Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112

Neuropsychopharmacology

Volumn 34, Issue 5, 2009, Pages 1277-1287

  Cannon, Dara M ^a,b   Klaver, Jacqueline M ^b   Peck, Summer A ^b   Rallis Voak, Denise ^b   Erickson, Kristine ^b   Drevets, Wayne C ^b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Anhedonia; Caudate; G protein coupled receptor; Striatum

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; CARBON 11; DOPAMINE 1 RECEPTOR; RADIOLIGAND;

ADULT; ANGER; ANHEDONIA; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; FEMALE; HEMISPHERE; HUMAN; MAJOR DEPRESSION; MALE; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; ORBITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POST HOC ANALYSIS; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; REWARD; SELF STIMULATION; VOLUNTARY MOVEMENT;

ADOLESCENT; ADULT; BASAL GANGLIA; BENZAZEPINES; BENZOFURANS; CARBON RADIOISOTOPES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D1; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 62349134479     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.194     Document Type: Article

References (98)

1. Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M et al (2000). Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20: 225-243.
2. Agren H, Reibring L (1994). PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry 27: 2-6.
3. Andersen PH, Gronvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C et al (1992). NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol 219: 45-52.
4. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). APA Press: Washington, DC.
5. Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z et al (2005). Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 89: 115-123.
6. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994). Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 116: 143-151.
7. Asberg M, Bertilsson L, Martensson B (1984). CSF monoamine metabolites, depression, and suicide. Adv Biochem Psychopharmacol 39: 87-97.
8. Bowden C, Theodorou A, Cheetham SC, Lowther S, Katona CL, Crompton MR et al (1997). Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res 752: 227-233.
9. Bremner JD, Vythilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA et al (2003). Regional brain metabolic correlates of alpha-methylparatyrosine- induced depressive symptoms: implications for the neural circuitry of depression. JAMA 289: 3125-3134.
10. Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A (2003). Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging. Am J Psychiatry 160: 1836-1841.
11. Camps M, Kelly PH, Palacios JM (1990). Autoradiographic localization of dopamine D 1 and D 2 receptors in the brain of several mammalian species. J Neural Transm Gen Sect 80: 105-127.
12. Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS et al (2007). Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [(11)C]DASB; comparison with bipolar disorder. Biol Psychiatry 62: 870-877.
13. Chou YH, Karlsson P, Halldin C, Olsson H, Farde L (1999). A PET study of D (1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology (Berl) 146: 220-227.
14. Cortes R, Gueye B, Pazos A, Probst A, Palacios JM (1989). Dopamine receptors in human brain: autoradiographic distribution of D1 sites. Neuroscience 28: 263-273.
15. De Keyser J, Dierckx R, Vanderheyden P, Ebinger G, Vauquelin G (1988). D1 dopamine receptors in human putamen, frontal cortex and calf retina: differences in guanine nucleotide regulation of agonist binding and adenylate cyclase stimulation. Brain Res 443: 77-84.
16. de la Fuente-Fernandez R, Kishore A, Calne DB, Ruth TJ, Stoessl AJ (2000). Nigrostriatal dopamine system and motor lateralization. Behav Brain Res 112: 63-68.
17. de la Mora MP, Cardenas-Cachon L, Vazquez-Garcia M, Crespo-Ramirez M, Jacobsen K, Hoistad M et al (2005). Anxiolytic effects of intra-amygdaloid injection of the D1 antagonist SCH23390 in the rat. Neurosci Lett 377: 101-105.
18. Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG et al (1995). Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology (Berl) 121: 317-322.
19. Dougherty DD, Bonab AA, Ottowitz WE, Livni E, Alpert NM, Rauch SL et al (2006). Decreased striatal D1 binding as measured using PET and [11C]SCH 23 390 in patients with major depression with anger attacks. Depress Anxiety 23: 175-177.
20. Drevets W, Gadde K, Krishnan K (2005). Neuroimaging studies of mood disorders. In: Charney D, Nestler E (eds). The Neurobiology of Mental Illness, 2 edn.
21. Drevets W (2008). Neural circuits underlying anhedonia in major depressive disorder. Biol Psychiatry 63(7 supplement 1): 110S.
22. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA et al (2001). Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49: 81-96.
23. Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D et al (1999). PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 21: 694-709.
24. Drevets WC, Price JL, Furey ML (2008). Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213: 93-118.
25. Ebert D, Feistel H, Loew T, Pirner A (1996). Dopamine and depression - striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl) 126: 91-94.
26. Ekelund J, Narendran R, Guillain O, Castrillon J, Hwang D, Slifstein M et al (2006). Pharmacological selectivity of the in vivo binding of [11C]NNC 112 and [11C]SCH 23390 in the cortex. A PET study in baboons. Neuroimage 31(Suppl 2): T111.
27. Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN et al (2007). In vivo DA D (1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 9: 117-125.
28. El-Ghundi M, Fletcher PJ, Drago J, Sibley DR, O'Dowd BF, George SR (1999). Spatial learning deficit in dopamine D (1) receptor knockout mice. Eur J Pharmacol 383: 95-106.
29. El-Ghundi M, O'Dowd BF, George SR (2001). Prolonged fear responses in mice lacking dopamine D1 receptor. Brain Res 892: 86-93.
30. Ferry AT, Ongur D, An X, Price JL (2000). Prefrontal cortical projections to the striatum in macaque monkeys: evidence for an organization related to prefrontal networks. J Comp Neurol 425: 447-470.
31. Fibiger HC (1991). The dopamine hypothesis of schizophrenia and mood disorders. In: Willner P, Scheel-Kruger J (eds). The Mesolimbic Dopamine System: From Motivation to Action. Wiley: New York. pp 615-638.
32. Fox PT, Mintun MA, Raichle ME, Miezin FM, Allman JM, Van Essen DC (1986). Mapping human visual cortex with positron emission tomography. Nature 323: 806-809.
33. Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD (1996). Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 4: 223-235.
34. Gerfen CR, Miyachi S, Paletzki R, Brown P (2002). D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22: 5042-5054.
35. Glick SD, Badalamenti JI (1986). Sex difference in reward asymmetry and effects of cocaine. Neuropharmacology 25: 633-637.
36. Glick SD, Ross DA, Hough LB (1982). Lateral asymmetry of neurotransmitters in human brain. Brain Res 234: 53-63.
37. Glick SD, Weaver LM, Meibach RC (1980). Lateralization of reward in rats: differences in reinforcing thresholds. Science 207: 1093-1095.
38. Glick SD, Weaver LM, Meibach RC (1981). Amphetamine enhancement of reward asymmetry. Psychopharmacology (Berl) 73: 323-327.
39. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW (2000). Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 20: 1208-1215.
40. Haber SN, Kim KS, Mailly P, Calzavara R (2006). Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. J Neurosci 26: 8368-8376.
41. Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sandell J et al (1998). Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med 39: 2061-2068.
42. Hamilton M (1959). The assessment of anxiety states by rating. Brit J Med Psychol 32: 50-55.
43. Hasler G, Fromm S, Carlson PJ, Luckenbaugh DA, Waldeck T, Geraci M et al (2008). Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry 65: 521-531.
44. Hirvonen J, Karlsson H, Kajander J, Markkula J, Rasi-Hakala H, Nagren K et al (2008). Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl) 197: 581-590.
45. Holmes A, Lachowicz JE, Sibley DR (2004). Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes. Neuropharmacology 47: 1117-1134.
46. Huang YY, Simpson E, Kellendonk C, Kandel ER (2004). Genetic evidence for the bidirectional modulation of synaptic plasticity in the prefrontal cortex by D1 receptors. Proc Natl Acad Sci USA 101: 3236-3241.
47. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H et al (2003). Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23: 1096-1112.
48. Iyo M, Yamasaki T (1993). The detection of age-related decrease of dopamine D1, D2 and serotonin 5-HT2 receptors in living human brain. Prog Neuropsychopharmacol Biol Psychiatry 17: 415-421.
49. Jenkinson M, Smith S (2001). A global optimisation method for robust affine registration of brain images. Med Image Anal 5: 143-156.
50. Karle J, Clemmesen L, Hansen L, Andersen M, Andersen J, Fensbo C et al (1995). NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (Berl) 121: 328-329.
51. Kato T (2007). Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 61: 3-19.
52. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA (2002). Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry 52: 740-748.
53. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W (1999). Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res 90: 91-101.
54. Koks S, Nikopensius T, Koido K, Maron E, Altmae S, Heinaste E et al (2006). Analysis of SNP profiles in patients with major depressive disorder. Int J Neuropsychopharmacol 9: 167-174.
55. Koo MS, Levitt JJ, Salisbury DF, Nakamura M, Shenton ME, McCarley RW (2008). A cross-sectional and longitudinal magnetic resonance imaging study of cingulate gyrus gray matter volume abnormalities in first-episode schizophrenia and first-episode affective psychosis. Arch Gen Psychiatry 65: 746-760.
56. Lalumiere RT, Nguyen LT, McGaugh JL (2004). Post-training intrabasolateral amygdala infusions of dopamine modulate consolidation of inhibitory avoidance memory: involvement of noradrenergic and cholinergic systems. Eur J Neurosci 20: 2804-2810.
57. Lambert G, Johansson M, Agren H, Friberg P (2000). Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 57: 787-793.
58. Laruelle M, Huang Y (2001). Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights. Q J Nucl Med 45: 124-138.
59. Links JM, Zubieta JK, Meltzer CC, Stumpf MJ, Frost JJ (1996). Influence of spatially heterogeneous background activity on hot object quantitation in brain emission computed tomography. J Comput Assist Tomogr 20: 680-687.
60. Liu ZH, Shin R, Ikemoto S (2008). Dual role of medial A10 dopamine neurons in affective encoding. Neuropsychopharmacology. February 6, 2008; ([epub ahead of print] doi: 10.1038/ npp.2008.4)
61. Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R et al (2001). Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 158: 314-316.
62. Martin-Soelch C, Infante A, Szczepanik J, Nugent A, Cannon D, Herscovitch P et al (2007). Lateralized dopaminergic response to reward in the human ventral striatum. Society for Neuroscience. p.311.315/FFF318.
63. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A et al (2001). Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12: 4121-4125.
64. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C (1998). A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond) 23: 207-214.
65. Montgomery AJ, Stokes P, Kitamura Y, Grasby PM (2007). Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J Affect Disord 101: 113-122.
66. Montgomery S, Asberg M (1979). A new depression scale designed to be sensitive to change. Brit J Psychiat 134: 382-389.
67. Nestler EJ, Carlezon Jr WA (2006). The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59: 1151-1159.
68. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL et al (2006). Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 67(Suppl 6): 46-49.
69. Ongur D, Ferry AT, Price JL (2003). Architectonic subdivision of the human orbital and medial prefrontal cortex. J Comp Neurol 460: 425-449.
70. Papp M, Klimek V, Willner P (1994). Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl) 115: 441-446.
71. Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M et al (2001). Dopamine D (2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 50: 313-322.
72. Pimoule C, Schoemaker H, Reynolds GP, Langer SZ (1985). [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol 114: 235-237.
73. Robbins TW (2000). Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res 133: 130-138.
74. Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S et al (1999). Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 56: 1101-1106.
75. Savitz J, van der Merwe L, Solms M, Ramesar R (2007). Lateralization of hand skill in bipolar affective disorder. Genes Brain Behav 6: 698-705.
76. Schultz W (1997). Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 7: 191-197.
77. Severino G, Congiu D, Serreli C, De Lisa R, Chillotti C, Del Zompo M et al (2005). A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 134B: 37-38.
78. Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T et al (1993). Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56: 467-472.
79. Silva MA, Topic B, Lamounier-Zepter V, Huston JP, Tomaz C, Barros M (2007). Evidence for hemispheric specialization in the marmoset (Callithrix penicillata) based on lateralization of behavioral/ neurochemical correlations. Brain Res Bull 74: 416-428.
80. Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M et al (2007). [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT (2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 27: 1733-1741.
81. Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T et al (1991). Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology (Berl) 103: 41-45.
82. Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A et al (1992). D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl) 106: 14-18.
83. Suzuki M, Hatano K, Sakiyama Y, Kawasumi Y, Kato T, Ito K (2001). Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and in vitro receptor autoradiography. Synapse 41: 285-293.
84. Swerdlow NR, Koob GF (1987). Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striatothalamic function. Behav Brain Sci 10: 197-245.
85. Tavares JV, Drevets WC, Sahakian BJ (2003). Cognition in mania and depression. Psychol Med 33: 959-967.
86. Todd RD, Carl J, Harmon S, O'Malley KL, Perlmutter JS (1996). Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. J Neurosci 16: 7776-7782.
87. Tomer R, Goldstein RZ, Wang GJ, Wong C, Volkow ND (2008). Incentive motivation is associated with striatal dopamine asymmetry. Biol Psychol 77: 98-101.
88. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM et al (2002). Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10: 36-43.
89. Waddington JL, Clifford JJ, McNamara FN, Tomiyama K, Koshikawa N, Croke DT (2001). The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). Prog Neuropsychopharmacol Biol Psychiatry 25: 925-964.
90. Wang Y, Chan GL, Holden JE, Dobko T, Mak E, Schulzer M et al (1998). Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse 30: 56-61.
91. Williams GV, Goldman-Rakic PS (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376: 572-575.
92. Willner P (1995). Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, pp 921-932.
93. Willner P (2000). Dopaminergic mechanisms in depression and mania. In: Bloom FaK, D (ed). Neuropsychopharmacology. The Fourth Generation of Progress, Raven Press, New York.
94. Wise RA, Rompre PP (1989). Brain dopamine and reward. Annu Rev Psychol 40: 191-225.
95. Woods RP, Cherry SR, Mazziotta JC (1992). Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16: 620-633.
96. Yamamoto BK, Lane RF, Freed CR (1982). Normal rats trained to circle show asymmetric caudate dopamine release. Life Sci 30: 2155-2162.
97. Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT et al (2008). Greater availability of dopamine transporters in patients with major depression - a dual-isotope SPECT study. Psychiatry Res 162: 230-235.
98. Zarate Jr CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD et al (2004). Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 56: 54-60.